No Data
No Data
Hang Seng Research lowered cms (00867.HK)'s target price to 7.7 yuan, expected to digest the impact of procurement with quantity in the first half of the year.
HSBC research report predicts that despite the improvement in the second half of last year, CMS Pharmaceuticals (00867.HK) will be affected by inventory clearance in the first half of this year. However, the growth of innovative drugs in the long term will not be affected by the launch of new drugs or business development. The bank has lowered the target price of the company from 8.5 yuan to 7.7 yuan and believes that the current valuation is reasonable, maintaining a "hold" rating. The bank stated that if there are clearer signs that the sales of innovative drugs can offset the impact of inventory clearance, it will have a more positive view of the stock. The report expects that the revenue and net profit of CMS Pharmaceuticals in the first half of this year will decrease by 21% and 57% respectively, to 3.6 billion yuan each.
Hang Seng Index Company: Graham's investment philosophy may still be applicable to today's Hong Kong stock market.
Hang Seng Index Company stated that inspired by the investment philosophy of the “father of value investing”, Benjamin Graham, the company screened a basket of value stocks from the Hong Kong stock market (represented by the Hang Seng Composite Index) based on seven criteria for analysis, including quality, financial leverage, liquidity, earnings growth, P/E ratio, P/B ratio, and dividend payout. From a ten-year backtest perspective, the dynamic basket of value stocks (market cap weighted) outperformed the market by 8.6 percentage points in terms of annualized total return, indicating that Graham's investment philosophy may still be applicable to today's Hong Kong stock market and may produce positive results.
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
HK stocks surged | cms(00867) rose more than 5% in the afternoon. Over the past year, the company has launched 5 innovative drugs, and the company has a rich pipeline of research and development.
CMS (00867) rose more than 5% in the afternoon. As of press time, it rose 4.78% to HKD 6.79, with a turnover of 43.6359 million HKD.
CMS (0867.HK): Innovative drugs will soon see significant growth with a rich pipeline of research and development.
Four innovative drugs have been included in medical insurance, and the fifth was approved for listing in June of this year. Three innovative drugs, namely Dexmedetomidine Nasal Spray, Toripalimab Injection and Methotrexate Injection- Silver Scaly Disease, have all been included in the national medical insurance catalog.
Mid-day overview: Hong Kong stocks are consolidating with the Hang Seng Index up nearly 2%; Mainland real estate is booming with Shimao Group up more than 14%.
Network technology rose, JD.com Group rose more than 4%, Meituan, Alibaba, Tencent Holdings, and Kuaishou all rose more than 2%.
No Data